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To summarize what we have learnt from this sym- 
posium, I will discuss the advantages and disadvantages 
of the use of fluoroquinolones in the treatment of 
respiratory tract infections. I will try to define the 
indications and first-line strategies for grepafloxacin 
use, consider some factors that have to be taken into 
consideration in these strategies, and describe the place 
of grepafloxacin versus the other quinolones. 
The question of cost-effectiveness remains, but is 
potentially in favor of the use of fluoroquinolones in 
the therapy of community-acquired LRTI. Are they 
able to reduce the cost of management of LRTI, 
considering that their broad spectrum and activity 
against penicillin- and macrolide-resistant organisms 
may favor their first-line use? 
DISADVANTAGES 
ADVANTAGES 
One of the advantages of using grepafloxacin in the 
treatment of lower respiratory tract infections (LRTI) 
is that it exhibits a broad spectrum of activity against 
major pathogens responsible for community-acquired 
LRTIs. There is a specific need for adequate cover of 
Streptococcur pneumoniae, and particularly to be able to 
deal with the increasing resistance of this organism to 
p-lactams and macrolides. 
Second, the bioavailability of those drugs that are 
given orally needs to be considered. We have learnt that 
grepafloxacin exhibits good bioavailability and favorable 
pharmacokinetics. 
Third, both theoretically and clinically, grepa- 
floxacin has a good tolerability profile. This is im- 
portant in the management of community-acquired 
infection, in which first-line therapy should be not only 
effective, but also well tolerated. Another desirable 
characteristic of a drug for the treatment of com- 
munity-acquired pneumonia (CAP) is to be able to 
switch from intravenous to oral therapy. 
Corresponding author and reprint requests: 
C. Carbon, Internal Medicine Unit, CHU Bichat, 
46 rue Henri Huchard, Paris F-75877 Cedex, France 
Tel: +33 1 4025 7000 Fax: c33 1 4025 8845 
A potential disadvantage of the use of fluoroquinolones 
is the possible development of resistance by some 
organisms. Among the pathogens responsible for 
community-acquired infections, the main problem 
in the future is likely to be the evolution of fluoro- 
quinolone resistance in S. pneumoniae. Careful surveil- 
lance to detect any such resistance development will be 
needed. Grepafloxacin probably does not cover a wide 
enough range of nosocomial pathogens and should not 
be considered for these indications. 
Side effects will be a disadvantage of some quino- 
lones. The potential for side effects with grepafloxacin 
is currently perceived as low, but they must be closely 
monitored once the compound is more widely used in 
the community. 
Drug-drug interactions also need to be considered. 
This may be of concern for some compounds in first- 
line use, particularly in the treatment of acute bacterial 
exacerbations of chronic bronchitis (ABECB), as many 
patients receive, concomitantly and chronically, drugs 
other than antibiotics. 
INDICATIONS 
One of the key questions is whether new fluoro- 
quinolones are able to niodifj our first-line strategies 
in the treatment of community-acquired infections. 
Can they be considered as first-line choice, or only as 
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second-line treatment? Can they be used as single-drug 
therapy? I think that they can be considered as first-line 
treatment, in accordance with the following. 
Community-acquired pneumonia 
In considering the types of patients with CAP 
who would be suitable for treatment with a new 
fluoroquinolone, we should probably refer to the 
classification proposed by the American Thoracic 
Society that divides patients with CAP into four 
categories [l]: 
1. 
2. 
3/4. 
Outpatients with pneumonia without co-morbidity and 
younger than 60 years Of age. The question of the 
general use of fluoroquinolones in this setting 
should be considered, probably after some cost- 
effectiveness studies have been performed in order 
to be sure that these compounds are able to save 
cost. 
Outpatients with pneumonia with co-morbidity and/ 
or older than 60 years. A fluoroquinolone can be 
considered as first-line choice, and can be used as 
single-drug therapy because fluoroquinolones are 
effective against S. pneumoniae, Mycoplasma and 
Legionella [2]. 
In categories 3 and 4, the use of new fluoro- 
quinolones may be restricted because they are 
oral drugs. The absence of data in very severe 
infections also precludes their use at the moment. 
Acute bacterial exacerbations of chronic bronchitis 
In ABECB, Dr Chodosh showed that this type of 
indication involves many types of patients. The 
questions raised today are whether the use of fluoro- 
quinolones should be restricted to severe cases and 
whether the aim is to try to reduce the number 
of exacerbations. We have to demonstrate that such 
compounds are able to increase the disease-free period 
in the chronic situation. 
Other infections 
With regard to upper respiratory tract infections, clearly 
the quinolones are not appropriate compounds in 
the treatment of pharyngitis. Currently, there is no 
information about pediatric use in acute otitis media. 
In the treatment of sinusitis, it still has to be 
decided whether there is an indication for fluoro- 
quinolones as first-line therapy in acute sinusitis, or 
whether they should, perhaps, be restricted to bacterio- 
logically documented chronic infections. 
From Professor Wise’s presentation, it seems that two 
major parameters should be considered in defining the 
dose and dosing interval: the ratio of peak to minimal 
inhibitory concentration (MIC), which is probably 
important because the quinolones exert a concen- 
tration-dependent killing, and is also important as an 
indicator of ability to avoid the selection of resistance; 
the ratio of the area under the concentration-time 
curve to MIC, which corresponds to the amount of 
drug delivered, and also correlates with efficacy. Thus, 
it is important to give the right dose, and in CAP it is 
probably important to use the highest tolerable dose, 
given once daily because of the long elimination half- 
life. Applying these two conditions may be the best way 
effectively to prevent resistance and ensure efficacy. The 
resistance profile of S. pneumoniae, and in some places 
such as Spain, of Haemophilur injuenzae need to be 
considered. 
Other important factors include controlling the 
conditions of use of fluoroquinolones to ensure that 
the types of diseases and patients for which they will 
be used are appropriate. This should help to avoid 
any underdosing in the treatment of respiratory tract 
infections and, concomitantly with the sui-veillance 
of clinical use and resistance patterns, control the 
development of resistance so as to help physicians 
modify their first-line treatment strategy. 
POSITIONING 
There will be several new quinolones coming onto the 
market in the near future; sparfloxacin, trovafloxacin, 
levofloxacin and BAY 128039. It will be important for 
grepafloxacin to be compared with and positioned 
with regard to those compounds. Clinical investigations 
show that grepafloxacin compares favorably with the 
other compounds against which it has been compared. 
The use of grepafloxacin in the most severe forms of 
respiratory tract infections, particularly in CAP with 
positive blood cultures of S. pneumoniae, remains to be 
investigated. 
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